Celldex Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Celldex Therapeutics, Inc. (CLDX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$54.75 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-25
- Celldex Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$54.75M, a 298.16% decline from fiscal 2024.
- Celldex Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $27.63M.
- Celldex Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$34.62M.
- Celldex Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$10.23M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | -$54.75M 10-K · filed 2026-02-25 |
| 2024-12-31 | $27.63M 10-K · filed 2026-02-25 |
| 2023-12-31 | -$34.62M 10-K · filed 2026-02-25 |
| 2022-12-31 | -$10.23M 10-K · filed 2025-02-27 |
| 2021-12-31 | -$11.16M 10-K · filed 2024-02-26 |
| 2020-12-31 | -$956.00K 10-K · filed 2023-02-28 |
| 2019-12-31 | $2.93M 10-K · filed 2022-02-28 |
| 2018-12-31 | -$28.81M 10-K · filed 2021-03-29 |
| 2017-12-31 | $66.29M 10-K · filed 2020-03-26 |
| 2016-12-31 | -$53.91M 10-K · filed 2019-03-07 |
| 2015-12-31 | -$57.09M 10-K · filed 2018-03-07 |
| 2014-12-31 | -$48.56M 10-K · filed 2017-03-14 |
| 2013-12-31 | -$35.76M 10-K/A · filed 2016-02-25 |
| 2012-12-31 | -$22.20M 10-K · filed 2015-02-24 |
| 2011-12-31 | -$19.01M 10-K · filed 2014-03-03 |
| 2010-12-31 | $11.53M 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |